Several preclinical studies have demonstrated the efficacy of direct GPX4 inhibitors such as RAS-selective lethal 3 (RSL3) and molecular libraries 162 (ML162) in inducing ferroptosis across a range of cancer models, including HNSCC [71]. This evidence concerns the gene GPX4 and cancer.